Mercy Doose Yough

Ms. Mercy Doose Yough


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MYMercy Doose Yough
Mercy Doose Yough
AAAmina Yusuf Ali
Amina Yusuf Ali
AAAmina Usman Abubakar
Amina Usman Abubakar
AMAdamu Umar Murba
Adamu Umar Murba
KIKunle Ijaya
Kunle Ijaya
MBMarycelin Mandu Baba
Marycelin Mandu Baba
Background: Poor storage of the polio vaccine in areas of inadequate or absent power to sustain the cold chain can compromise its potency. This study assessed the sustainability of the bOPV vaccine potency using viral titer and the colour of the vaccine vial monitor (VVM) when stored in the refrigerator, room, incubators, and at atmospheric temperatures over time. Method: The standardized World Health Organization (WHO) protocol was used to determine the vaccine titers weekly until the VVM degraded to 100%. Weekly average temperatures of the vaccine storage conditions were also obtained. Results: The fifty vials of bOPV tested before exposure had titers above the WHO minimum values, and VVM rated at 0% degradation. Eight of ten vials of bOPV stored in the refrigerator sustained potency for six months, with the color of VVM at 0% and 10% in five and six months, respectively. At room temperature, nine of ten vaccine vials retained potency up to three weeks, and the VVM degradation rates were 10 %, 20%, 40% and 100% after one, two, three, and four weeks, respectively. The potency of twenty vials of bOPV in the incubator was sustained for a week, and the VVM degraded by 10%, 50% and 100 % at one, two, and three weeks, respectively. At atmospheric temperature, the titers significantly dropped, and the VVM was at 100% degradation within a week. Conclusion: The potency of bOPV was most preserved under refrigeration, moderately compromised at room temperature, and severely degraded at incubator temperatures over time.

1 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAmina Yusuf Ali
Amina Yusuf Ali
MYMercy Doose Yough
Mercy Doose Yough
AYAbubakar Yakubu
Abubakar Yakubu
JAJane Oowo Anyiam
Jane Oowo Anyiam
BEBashir Adebayo Elegbele
Bashir Adebayo Elegbele
MBMarycelin Mandu Baba
Marycelin Mandu Baba
Background: This study monitored the viral content of the Novel Oral Polio Vaccine Type 2 (nOPV2) and VVM degradation during storage at different temperatures over a specified period. Method: Weekly vaccine titers were obtained until the vaccine vial monitor (VVM) degraded to 100%, except when stored in a refrigerator. Results: At refrigerator temperature, 90% and 10% of the vaccine vials retained potency for six and seven months, respectively, but none retained potency at 8 to 9 months. The median survival time was approximately seven months. The VVM remained at 0% degradation up to 4 months and changed to 5%, 10%, 20%, 30%, and 40% after 5, 6,7,8 and nine months, respectively. At room temperature, the nOPV2 retained potency during the first two weeks, declined by the third week, and none retained potency by the fourth week. The degradation of the VVM was rated 10 %, 30%, 60%, and 100% after one, two, three, and four weeks of storage, respectively. The median survival time at incubator temperature was one week, during which 10% and 90% of the vaccine in batches 2 and 1, respectively, survived, but all vials reached 0.0% at week 3. At atmospheric temperature, the survival probability was zero within a week of exposure. Time accounted for over 80% of the variation in vaccine titer. Conclusion: The potency of the nOPV2 was preserved under refrigeration for seven months, at room temperature for two weeks, in an incubator for a week, and severely degraded at atmospheric temperatures within a week.